Defueling the cancer: ATP synthase as an emerging target in cancer therapy
Reprogramming of cellular metabolism is a hallmark of cancer. Mitochondrial ATP synthase (MAS) produces most of the ATP that drives the cell. High expression of the MAS-composing proteins is found during cancer and is linked to a poor prognosis in glioblastoma, ovarian cancer, prostate cancer, breas...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-12-01
|
| Series: | Molecular Therapy: Oncolytics |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2372770521001261 |
| _version_ | 1819095352220844032 |
|---|---|
| author | Ting Wang Fei Ma Hai-li Qian |
| author_facet | Ting Wang Fei Ma Hai-li Qian |
| author_sort | Ting Wang |
| collection | DOAJ |
| description | Reprogramming of cellular metabolism is a hallmark of cancer. Mitochondrial ATP synthase (MAS) produces most of the ATP that drives the cell. High expression of the MAS-composing proteins is found during cancer and is linked to a poor prognosis in glioblastoma, ovarian cancer, prostate cancer, breast cancer, and clear cell renal cell carcinoma. Cell surface-expressed ATP synthase, translocated from mitochondrion to cell membrane, involves the angiogenesis, tumorigenesis, and metastasis of cancer. ATP synthase has therefore been considered a therapeutic target. We review recent various ATP synthase inhibitors that suppress tumor growth and are being tested for the clinic. |
| first_indexed | 2024-12-21T23:41:56Z |
| format | Article |
| id | doaj.art-d8f1f1065edc47adbc11845b9e8eeb0d |
| institution | Directory Open Access Journal |
| issn | 2372-7705 |
| language | English |
| last_indexed | 2024-12-21T23:41:56Z |
| publishDate | 2021-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Therapy: Oncolytics |
| spelling | doaj.art-d8f1f1065edc47adbc11845b9e8eeb0d2022-12-21T18:46:12ZengElsevierMolecular Therapy: Oncolytics2372-77052021-12-01238295Defueling the cancer: ATP synthase as an emerging target in cancer therapyTing Wang0Fei Ma1Hai-li Qian2State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, Peking University Cancer Hospital & Institute, Beijing 100021, ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; Corresponding author: Fei Ma, PhD, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; Corresponding author: Hai-li Qian, PhD, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.Reprogramming of cellular metabolism is a hallmark of cancer. Mitochondrial ATP synthase (MAS) produces most of the ATP that drives the cell. High expression of the MAS-composing proteins is found during cancer and is linked to a poor prognosis in glioblastoma, ovarian cancer, prostate cancer, breast cancer, and clear cell renal cell carcinoma. Cell surface-expressed ATP synthase, translocated from mitochondrion to cell membrane, involves the angiogenesis, tumorigenesis, and metastasis of cancer. ATP synthase has therefore been considered a therapeutic target. We review recent various ATP synthase inhibitors that suppress tumor growth and are being tested for the clinic.http://www.sciencedirect.com/science/article/pii/S2372770521001261mitochondrial ATP synthasecancer metabolismmitochondrial metabolismATP synthase inhibitorchemotherapy |
| spellingShingle | Ting Wang Fei Ma Hai-li Qian Defueling the cancer: ATP synthase as an emerging target in cancer therapy Molecular Therapy: Oncolytics mitochondrial ATP synthase cancer metabolism mitochondrial metabolism ATP synthase inhibitor chemotherapy |
| title | Defueling the cancer: ATP synthase as an emerging target in cancer therapy |
| title_full | Defueling the cancer: ATP synthase as an emerging target in cancer therapy |
| title_fullStr | Defueling the cancer: ATP synthase as an emerging target in cancer therapy |
| title_full_unstemmed | Defueling the cancer: ATP synthase as an emerging target in cancer therapy |
| title_short | Defueling the cancer: ATP synthase as an emerging target in cancer therapy |
| title_sort | defueling the cancer atp synthase as an emerging target in cancer therapy |
| topic | mitochondrial ATP synthase cancer metabolism mitochondrial metabolism ATP synthase inhibitor chemotherapy |
| url | http://www.sciencedirect.com/science/article/pii/S2372770521001261 |
| work_keys_str_mv | AT tingwang defuelingthecanceratpsynthaseasanemergingtargetincancertherapy AT feima defuelingthecanceratpsynthaseasanemergingtargetincancertherapy AT hailiqian defuelingthecanceratpsynthaseasanemergingtargetincancertherapy |